The Postanesthesia Care Unit - Considerations for Pediatric Recovery

The Postanesthesia Care Unit - Considerations for Pediatric Recovery is a topic covered in the Clinical Anesthesia Procedures.

To view the entire topic, please or .

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drugs, procedures, and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and PRIME Journals. Explore these free sample topics:

-- The first section of this topic is shown below --

PONV

PONV is more common in the pediatric surgery population than in adults; however, children under the age of 2 years old are exceptions and have a reduced incidence relative to adults. Certain operations (adenotonsillectomy, strabismus repair, hernia repair, orchidopexy, and penile surgery) are associated with increased incidence for PONV. Risk factors, as well as the general principles for prevention and treatment, are similar to those described in adults. There is reasonable evidence to suggest ondansetron (100 μg/kg IV bolus for <6 months old; 150 μg/kg IV bolus >6 months old up to 4 mg) and dexamethasone (62.5 to 500 μg/kg up to 8 mg) are superior to other drugs in the prevention of PONV in children.

-- To view the remaining sections of this topic, please or --

PONV

PONV is more common in the pediatric surgery population than in adults; however, children under the age of 2 years old are exceptions and have a reduced incidence relative to adults. Certain operations (adenotonsillectomy, strabismus repair, hernia repair, orchidopexy, and penile surgery) are associated with increased incidence for PONV. Risk factors, as well as the general principles for prevention and treatment, are similar to those described in adults. There is reasonable evidence to suggest ondansetron (100 μg/kg IV bolus for <6 months old; 150 μg/kg IV bolus >6 months old up to 4 mg) and dexamethasone (62.5 to 500 μg/kg up to 8 mg) are superior to other drugs in the prevention of PONV in children.

There's more to see -- the rest of this entry is available only to subscribers.